Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.65 |
| ▸ | CDK2 | P24941 | 6/20 | 0.64 |
| ▸ | CDK1 | P06493 | 3/20 | 0.64 |
| ▸ | NEK2 | P51955 | 2/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.64 |
| ▸ | CDK7 | P50613 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | LYN | P07948 | 1/20 | 0.64 |
| ▸ | MET | P08581 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.64 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | AKT2 | P31751 | 1/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16146412 | 0.85 | POLA1 (0.74) | POLA1CDK2CDK1NEK2CHEK1 | |
| SCHEMBL16146840 | 0.85 | POLA1 (0.66) | POLA1CDK2CDK1NEK2CHEK1 | |
| SCHEMBL16146749 | 0.85 | POLA1 (0.66) | POLA1CDK2CDK1NEK2CHEK1 | |
| SCHEMBL16146409 | 0.84 | BRAF (0.66) | POLA1CDK2CDK1NEK2CHEK1 | |
| SCHEMBL16146610 | 0.84 | POLA1 (0.71) | POLA1CDK2CDK1NEK2CHEK1 | |
| SCHEMBL16146374 | 0.84 | BRAF (0.66) | POLA1CDK2CDK1NEK2CHEK1 | |
| SCHEMBL459414 | 0.83 | ADORA3 (0.68) | CDK2CDK1NEK2CHEK1CDK7 | |
| SCHEMBL16147002 | 0.82 | CDK2 (0.64) | CDK2CDK1NEK2CHEK1CDK7 | |
| SCHEMBL8539783 | 0.82 | CDK2 (0.64) | POLA1CDK2CDK1NEK2CHEK1 | |
| SCHEMBL16146628 | 0.80 | POLA1 (0.63) | POLA1CDK2CDK1NEK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108703970-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2018-10-26 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-108703970-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2018-10-26 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| EP-3277843-A2 | METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING | Cellular Research, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-7662798-B2 | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | POLA1 2876/4885CDK2 1757/4885CDK1 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.